Mofezolac
|
|
|
- CAS-Nr.
- 78967-07-4
- Englisch Name:
- Mofezolac
- Synonyma:
- N-22;Disopain;Mofezolac;Mofezolac, 10 mM in DMSO;3,4-Bis(4-methoxyphenyl)isoxazole-5-acetic acid;3,4-Bis(4-methoxyphenyl)-5-isoxazoleacetic acid;5-Isoxazoleacetic acid, 3,4-bis(4-methoxyphenyl)-;2-(3,4-bis(4-Methoxyphenyl)isoxazol-5-yl)acetic acid;α-[3,4-Bis(4-methoxyphenyl)-5-isoxazolyl]acetic acid;2-[3,4-bis(4-methoxyphenyl)-1,2-oxazol-5-yl]acetic acid
- CBNumber:
- CB7875698
- Summenformel:
- C19H17NO5
- Molgewicht:
- 339.34
- MOL-Datei:
- 78967-07-4.mol
|
Mofezolac Eigenschaften
- Schmelzpunkt:
- 147.5℃
- Siedepunkt:
- 527.2±50.0 °C(Predicted)
- Dichte
- 1.250±0.06 g/cm3(Predicted)
- storage temp.
- 2-8°C
- L?slichkeit
- DMSO: soluble
- Aggregatzustand
- A solid
- pka
- pKa ~3.3(at 25℃)
- Farbe
- White to off-white
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Toxizit?t |
LD50 in male, female mice, male, female rats (mg/kg): 1528, 1740, 920, 887 orally; 275, 321, 378, 342 i.p.; 612, 545, 572, 510 s.c. (Satoh) |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H317 |
Kann allergische Hautreaktionen verursachen. |
Sensibilisierung der Haut |
Kategorie 1A |
Warnung |
|
P261, P272, P280, P302+P352,P333+P313, P321, P363, P501 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P305+P351+P338,P337+P313P |
|
| Sicherheit |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Mofezolac Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Mofezolac is a new non-steroidal analgesic antiinflammatory agent introduced in
Japan for the treatment of post-operative and post-traumatic pain, acute upper
respiratory tract pain, osteoarthritis, and lumbago. In in vfim studies, mofezolac
inhibits prostaglandin biosynthesis and platelet aggregation, reportedly through the
inhibition of cyclooxygenase. In animal studies, mofezolac showed more potent
suppression in various writhing models than agents such as ibuprofen, mefenamic
acid and aspirin. Mofezolac also has a potent inhibitory activity on the algesic
responses induced by the mechanical stimulus of the inflamed tissue. The
ulcerogenic effect of mofezolac on the gastric mucosa is far weaker than that of
indomethacin and other agents.
Originator
Pasteur Merieux (France)
Trademarks
Disopain
Mofezolac Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Mofezolac Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 59)Lieferanten
- Mofezolac
- 3,4-Bis(4-methoxyphenyl)isoxazole-5-acetic acid
- Disopain
- N-22
- α-[3,4-Bis(4-methoxyphenyl)-5-isoxazolyl]acetic acid
- 2-(3,4-bis(4-Methoxyphenyl)isoxazol-5-yl)acetic acid
- 3,4-Bis(4-methoxyphenyl)-5-isoxazoleacetic acid
- 5-Isoxazoleacetic acid, 3,4-bis(4-methoxyphenyl)-
- Mofezolac,inhibit,platelet,COX,Inhibitor,aggregation,NSAID,Cyclooxygenase,pain,anti-inflammatory,COX-1,analgesic
- 2-[3,4-bis(4-methoxyphenyl)-1,2-oxazol-5-yl]acetic acid
- Mofezolac, 10 mM in DMSO
- 78967-07-4
